mitomycin and Pseudophakia

mitomycin has been researched along with Pseudophakia in 13 studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Pseudophakia: Presence of an intraocular lens after cataract extraction.

Research

Studies (13)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Anti-glaucoma Medications

(NCT00940823)
Timeframe: 5 years

Intraocular Pressure (IOP)

(NCT00940823)
Timeframe: 5 years

LogMAR Snellen Visual Acuity

Visual acuity (VA) was tested monocularly (one eye at a time) using the manifest refraction adjusted for optical infinity using a standard Snellen Visual Acuity chart at 20 feet. Normal vision, or 20/20 vision, means that the participant can see at 20 feet what a healthy control can also see at 20 feet. Legal blindness, or 20/200 vision, means the participant can see at 20 feet what a healthy control can see at 200 feet. Hence, an increasing denominator implies visual impairment. Counting fingers was designated as 20/2000 vision, hand motions was 20/16000, light perception was 20/32000 and no light perception was 20/64000. To allow for appropriate statistical analysis, logMAR Snellen Visual Acuity was calculated using the formula: -logMAR (Snellen Acuity). This means that normal vision (20/20) would correspond to a value of 0, legal blindness (20/200) would correspond to a value of 1, and no light perception (20/64000) would correspond to 3.5. (NCT00940823)
Timeframe: 5 years

Number of Participants With Complications During or After Surgery

(NCT00940823)
Timeframe: 5 years

Number of Participants With Interventions After Surgery

(NCT00940823)
Timeframe: 5 years

Number of Participants With Surgical Failure (Composite Measure)

"IOP out of target range (5-18 mmHg inclusive) or <20% reduction from baseline for 2 consecutive visits after 3 months.~De novo glaucoma surgery required (e.g., cyclodestructive procedure, additional tube shunt).~Removal of the implant.~Severe vision loss related to the surgery (endophthalmitis, suprachoroidal hemorrhage with vision loss, enucleation, evisceration, or phthisis bulbi) or progression to no light perception for any reason." (NCT00940823)
Timeframe: 5 years

Trials

1 trial available for mitomycin and Pseudophakia

Other Studies

12 other studies available for mitomycin and Pseudophakia